Citations

Clear

371 citation(s) found for "Cho, B".

Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study
Subbiah, Vivek , Schüler, Martin , Zhu, Viola W. , Hadoux, Julien , Curigliano, Giuseppe , Wirth, Lori J. , Gainor, Justin F. , Alonso, Guzmán , Adkins, Douglas, Godbert, Yann , Ahn, Myung‐Ju , Cassier, Philippe A. , Cho, Byoung Chul , Zalutskaya, Alena , Barata, Teresa, Trask, Peter C., Scalori, Astrid, Bordogna, Walter, Heinzmann, Sebastian , Brose, Marcia S. , Hadoux, Julien , Curigliano, Giuseppe , Subbiah, Vivek , Hu, Mimi I. , Mansfield, Aaron S. , Taylor, Matthew H. , Adkins, Douglas, Lin, Chia‐Chi , Zalutskaya, Alena A. , Cho, B , Schuler, M.

Mayo Clinic

Thyroid® | November 27, 2023 | Volume: 34 | Issue: 1 | Pages: 26-40

10.1089/thy.2023.0363 | PMID 38009200 Get It

Background: Rearranged during transfection ( RET ) alterations are targetable oncogenic drivers in thyroid cancer. Primary data from the open-label, phase 1/2 ARROW study demonstrated clinical activity and manageable safety with pralsetinib, a selective RET inhibitor, in patients with advanced/metastatic RET -altered thyroid cancer. We present an updated analysis with more patients and longer follow-up. Methods: Adult patients with advanced/metastatic RET -mutant medullary thyroid cancer (MTC) or RET fusion-positive thyroid cancer who initiated oral pralsetinib at 400 mg once daily were included. Primary endpoints were overall response rate (ORR) by blinded independent central review (per RECIST v1.1) and safety. Secondary endpoints included duration of response (DoR), progression-free survival (PFS), and overall survival. Responses were assessed in three cohorts of patients with baseline measurable disease: patients with RET -mutant MTC who had received prior cabozantinib and/or vandetanib (C/V), treatment-naïve patients with RET -mutant MTC, and patients with previously treated RET fusion-positive thyroid cancer. Patient-reported outcomes (PROs) were an exploratory endpoint. Results: As of October 18, 2021, the measurable disease population comprised of 61 patients with RET -mutant MTC and prior C/V, 62 treatment-naïve patients with RET -mutant MTC, and 22 patients with RET fusion-positive thyroid cancer who had received prior systemic therapy, including radioactive iodine. The ORR was 55.7% [confidence interval; 95% CI: 42.4–68.5] in patients with RET -mutant MTC and prior C/V, 77.4% [95% CI: 65.0–87.1] in treatment-naïve patients with RET -mutant MTC, and 90.9% [95% CI: 70.8–98.9] in patients with previously treated RET fusion-positive thyroid cancer. Median DoR and median PFS were both 25.8 months in patients with RET -mutant MTC and prior C/V, not reached in treatment-naïve patients with RET -mutant MTC, and 23.6 and 25.4 months, respectively, in patients with previously treated RET fusion-positive thyroid cancer. In the RET -altered thyroid cancer safety population ( N = 175), 97.1% of patients reported a treatment-related adverse event (TRAE); these led to discontinuation in 5.7% and dose reduction in 52.6% of patients. There was one death (0.6%) due to a TRAE. PROs improved or remained stable after pralsetinib treatment. Conclusions: In this updated analysis of the ARROW study, pralsetinib continued to show deep and durable clinical activity and a manageable safety profile in patients with advanced/metastatic RET- altered thyroid cancer. Clinical Trial Registration: NCT03037385
Adenosine A2A Receptor Driven Impulsivity Promotes Cue‐Dependent Reward Seeking Behavior and Increases Hippocampal Immature Neurons
Oliveros, Alfredo , Cho, Chang Hoon , Choi, Sun, Jang, Mi‐Hyeon , Choi, Doo‐Sup

Mayo Clinic

The FASEB Journal | November 26, 2023 | Volume: 30 | Issue: S1 | Pages: No page available

10.1096/fasebj.30.1_supplement.704.8 Get It

Mice lacking the ethanol‐sensitive equilibrative nucleoside adenosine transporter 1 (ENT1 –/– ) display enhanced goal‐directed behaviors due to decreased adenosine A 2A R function. However, the role of A 2A R signaling in the regulation of impulsivity remains unknown. Using Pavlovian conditioning, second‐order schedule discrimination, and the 5‐choice serial reaction time task (5‐CSRTT), which incorporates differential‐reward of low rate (DRL) schedules, we reveal that deficits in A 2A R function promote impulsivity. ENT1 –/– mice display exaggerated impulsive responses and faster reaction times to retrieve reward during conditioning and extinction. Interestingly, our results show that basal ERK1/2 phosphorylation is reduced in the dorsal hippocampus (dHPC) of ENT1 –/– mice and that impulsive Pavlovian conditioning significantly increases ERK1/2 phosphorylation. Subsequently, we validate that inhibition of A 2A R promotes impulsivity during Pavlovian conditioning and the 5‐CSRTT. In addition to increased ERK1/2 phosphorylation, mice demonstrating exaggerated impulsivity as a result of A 2A R inhibition exhibit enhanced expression of doublecortin and increased incorporation of BrdU within the HPC. Taken together, these findings indicate that impaired ENT1/A 2A R signaling promotes impulsivity during cue‐induced conditioning and contributes to reward seeking during extinction. More importantly, these results demonstrate that impulsive behavior is associated with aberrant hippocampal neurogenesis, which may contribute to the development of maladaptive reward‐seeking behaviors. Support or Funding Information NIH R01 AA018779
Real-World Outcomes with Immuno-Oncology Therapies in Advanced Melanoma: Final Results of the OPTIMIzE Registry Study
Kirkwood, John M. , Kottschade, Lisa A. , McWilliams, Robert R. , Khushalani, Nikhil I. , Jang, Sekwon, Hallmeyer, Sigrun , McDermott, David H. , Tawbi, Hussein A. , Che, Min , Lee, Cho-Han, Ritchings, Corey , Le, Trong Kim , Park, Boas, Ramsey, Scott D. , McDermott, David F , Tawbi, Hussein , Ramsey, Scott , McWilliams, Robert R , Khushalani, Nikhil I

Mayo Clinic

Immunotherapy | November 8, 2023 | Volume: 16 | Issue: 1 | Pages: 29-42

10.2217/imt-2022-0292 | PMID 37937397 Get It

729 A first-in-human, open-label, multicenter, phase 1/2a, dose escalation and expansion study of GI-102, a novel immunocytokine combining CD80-IL2v3, in patients with advanced or metastatic solid tumors
Lee, Jeeyun , Campian, Jian , Zhao, Yujie , Seetharam, ­Mahesh , Adjei, Alex A. , Yun, Nari, Lee, Woo-Sun, Lee, Wooyul, Park, Sosun, Seo, Bochan, Lee, Kyungwha, Park, Chong Woo, Cho, Byoung Chul , Lee, Jae‐Lyun , Lee, Jung-Yun , Wee, Wen , Chae, Dongwoo , Jang, Myoung Ho

Mayo Clinic

Regular and Young Investigator Award Abstracts | October 31, 2023 | Volume: No volume available | Issue: No issue available | Pages: A824-A824

10.1136/jitc-2023-sitc2023.0729 Get It

O065 Autonomic Dysregulation During Sleep in Parkinsonian Spectrum Disorders
Levendowski, Daniel J. , Cho, Y , Walsh, Christine M. , Lee‐Iannotti, Joyce , Mazieka, G, Cho, Y, Tsuang, Debby W. , Berka, Chris , Boeve, Bradley F. , Neylan, Thomas C. , Louis, Erik K. St.

Mayo Clinic

Sleep Advances | October 23, 2023 | Volume: 4 | Issue: Supplement_1 | Pages: A26-A26

10.1093/sleepadvances/zpad035.065 Get It

Abstract Introduction Symptoms associated with autonomic nervous system dysfunction are common to patients with neurodegenerative disorders (NDD) resulting from the accumulation of α-synuclein in the neurons and glial cells. In this study we investigate whether a novel biomarker, the autonomic activation index, can discriminate these potentially affected NDD groups. Methods After ethics review and with informed consent, patients with Lewy body disease (DLB/PDD: n=20%), Alzheimer’s disease dementia (AD: n=27), Parkinson disease (PD: n=14), mild cognitive impairment (MCI: n=37), isolated REM sleep behavior disorder (iRBD: n=15) and a control group (CG: n=58) were studied with the Sleep Profiler. AAI was based on a 6 BPM increase in pulse rate compared to the previous/subsequent 10th second. Between-group comparisons were assessed with Mann-Whitney U and Chi-square tests. Results The AAI values for the DLB/PDD patients were decreased compared to the AD, MCI (both p<0.03), and CG (p<0.0005), while the PD was less than AD and MCI (both < 0.05) and CG (p<0.002). The proportions of cases with abnormal AAI values (<10 events/h) was greatest in DLB/PDD patients, and greater than in ADem (p<0.02), MCI (p<0.02) and CG (p<0.0001), while AAI in PD and iRBD was greater than in CG (p<0.007 and 0.05 respectively). Conclusions These findings suggest that the AAI can be used to objectively confirm subjective complaints of autonomic dysfunction symptoms in patients with synucleinopathies. Longitudinal studies are needed determine factors that influence changes in the AAI.
Clonal Somatic Mutations in Chronic Lung Diseases Are Associated with Reduced Lung Function
Yun, Jeong H. , Khan, Mehnaz, Ghosh, Auyon , Hobbs, Brian D. , Hersh, Craig P. , Cool, Carlyne D. , Barwick, Lucas, Flaherty, Kevin R. , Criner, Gerard J. , Brown, Kevin K. , Silverman, Edwin K. , DeMeo, Dawn L. , Bick, Alexander G. , Hersh, Craig P , Wise, Robert , Cho, Michael H , Ghosh, Auyon J , Yun, Jeong H , Bick, Alexander G , Criner, Gerard , Hobbs, Brian D , Castaldi, Peter J. , Miller, Peter G. , Sciurba, Frank C. , Limper, Andrew H. , Wise, Robert A. , Martínez, Fernando J. , Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | October 3, 2023 | Volume: 208 | Issue: 11 | Pages: 1196-1205

10.1164/rccm.202303-0395oc | PMID 37788444 Get It

Abstract Rationale Constantly exposed to the external environment and mutagens such as tobacco smoke, human lungs have one of the highest somatic mutation rates among all human organs. However, the relationship of these mutations to lung disease and function is not known. Objectives To identify the prevalence and significance of clonal somatic mutations in chronic lung diseases. Methods We analyzed the clonal somatic mutations from 1,251 samples of normal and diseased noncancerous lung tissue RNA sequencing with paired whole-genome sequencing from the Lung Tissue Research Consortium. We examined the associations of somatic mutations with lung function, disease status, and computationally deconvoluted cell types in two of the most common diseases represented in our dataset, chronic obstructive pulmonary disease (COPD; 29%) and idiopathic pulmonary fibrosis (IPF; 13%). Measurements and Main Results Clonal somatic mutational burden was associated with reduced lung function in both COPD and IPF. We identified an increased prevalence of clonal somatic mutations in individuals with IPF compared with normal control subjects and individuals with COPD independent of age and smoking status. IPF clonal somatic mutations were enriched in disease-related and airway epithelial–expressed genes such as MUC5B in IPF. Patients who were MUC5B risk variant carriers had increased odds of developing somatic mutations of MUC5B that were explained by increased expression of MUC5B. Conclusions Our identification of an increased prevalence of clonal somatic mutation in diseased lung that correlates with airway epithelial gene expression and disease severity highlights for the first time the role of somatic mutational processes in lung disease genetics.
Fecal Microbiota Transplantation Is Effective for Postcolectomy Recurrent Clostridioides difficile Infection
Cho, Janice , Roque, Maria Vazquez , Orenstein, Robert , Loftus, Edward V. , DiBaise, John K. , Pardi, Darrell S. , Khanna, Sahil , Loftus, Edward V

Mayo Clinic

Journal of Gastrointestinal Infections | September 22, 2023 | Volume: 12 | Issue: 01 | Pages: 036-040

10.1055/s-0042-1757197 Get It

Background The outcomes from fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (rCDI) in patients after complete or partial colectomy are not well-defined. Objectives We sought to report our experience with FMT for rCDI in patients who have undergone colectomy. Methods Descriptive analyses of FMT outcomes from 2014 to 2020 were performed in patients who previously had undergone complete or partial colectomy. Results Twenty-nine patients with prior colectomy for inflammatory bowel disease, malignancy, slow-transit constipation refractory to medical therapy, or fulminant CDI underwent FMT for rCDI. Two patients (6.9%) had rCDI within 8 weeks post-FMT. Seven had CDI beyond 8 weeks (median 10 months) with 71% related to antibiotic exposure post-FMT, suggesting a 69% overall success. Conclusion FMT resolves rCDI in most patients after colectomy with subsequent antibiotic exposure predicting CDI after FMT.
Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Cho, Hanna , Mundada, Nidhi S. , Apostolova, Liana G. , Carrillo, María C. , Shankar, Ranjani , Amuiri, Alinda, Zeltzer, Ehud , Windon, Charles , Soleimani‐Meigooni, David N. , Tanner, Jeremy A. , Lesman‐Segev, Orit H. , Aisen, Paul , Eloyan, Ani , Lee, Hye Sun , Hammers, Dustin B. , Kirby, Kala, Dage, Jeffrey L. , Fagan, Anne M. , Grinberg, Lea T. , Jack, Clifford R. , Kramer, Joel H. , Kukull, Walter A. , Vemuri, Prashanthi , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Riddle, Meghan , Rogalskı, Emily , Salloway, Stephen , Sha, Sharon, Turner, Raymond Scott , Wingo, Thomas S. , Joie, Renaud La , Rabinovici, Gil D. , Jack, Clifford R , Vemuri, Prashanthi , Day, Gregory S , La Joie, Renaud , Grinberg, Lea , Rabinovici, Gil D , Windon, Charles , Wingo, Thomas S , Dage, Jeffrey L , Lawhn-Heath, Courtney A. , Hammers, Dustin B , Foroud, Tatiana , Murray, Melissa E. , Nudelman, Kelly , Toga, Arthur W. , Atri, Alireza , Duara, Ranjan , Honig, Lawrence S. , Jones, David T. , Masdeu, Joseph C , Musiek, Erik , Sha, Sharon J. , Wolk, David A. , Koeppe, Robert A. , Iaccarino, Leonardo , Dickerson, Bradford Clark

Mayo Clinic

Alzheimer's & Dementia | September 10, 2023 | Volume: 19 | Issue: S9 | Pages: No page available

10.1002/alz.13453 | PMID 37690109 Get It

Abstract INTRODUCTION We aimed to describe baseline amyloid‐beta (Aβ) and tau‐positron emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study (LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's disease (EOAD). METHODS We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ−) based on the combination of visual read by expert reader and image quantification. RESULTS 243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid‐PET; 231 (95.1%) of them were tau‐PET positive (A+T+). Tau‐PET signal was elevated across cortical regions with a parietal‐predominant pattern, and higher burden was observed in younger and female EOAD participants. DISCUSSION LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau‐PET binding at baseline might have implications for therapeutic strategies in patients with EOAD. HIGHLIGHTS 72% of patients with clinical EOAD were positive on both amyloid‐ and tau‐PET. Amyloid‐positive patients with EOAD had high tau‐PET signal across cortical regions. In EOAD, tau‐PET mediated the relationship between amyloid‐PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau‐PET.
Electronic Patient-Reported Outcome Data Collection Systems in Oncology Clinical Trials: A Survey of Clinical Research Professionals (an Alliance Study)
Cho, Youmin , Zahrieh, David , Chow, Selina , Williams, David A. , Arnault, Denise Saint , Jiang, Yun , Lavoie Smith, Ellen M , Zahrieh, David , Williams, David A , Saint Arnault, Denise , Jiang, Yun

Mayo Clinic

JCO Clinical Cancer Informatics | September 7, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/cci.23.00007 | PMID 37677111 Get It

PURPOSE To describe clinical research professionals (CRPs)’ experiences with electronic patient-reported outcome (ePRO) data collection systems in oncology clinical trials and identify correlates of CRPs' attitude toward technology. METHODS An online survey was conducted among 210 CRPs from 125 National Cancer Institute–funded research sites. Measures included CRPs' demographic characteristics, working years, employment locations, and previous experiences with various types of ePROs. Their attitude toward technology was measured by the Technology Attitude Scale-Adapted. The Wilcoxon signed-rank test was used to compare two subdomains of attitude (perceived usefulness [PU] and perceived ease of use [PEU]). Multiple linear regression was used to explore correlates of (1) overall attitude, (2) PU, and (3) PEU. The significance level was 5%. RESULTS Participants' median age was 41 years (range, 21-67). Most were female (90%) and White (82%). More than half of the participants had previous experiences with web-based ePROs using patients' own devices (72%) or site-/sponsor-provided on-site devices (eg, kiosks or tablets; 64%). CRPs who were 60 years or older (β = −0.32, P < .05) or worked for 10-20 years (β = −0.11, P < .05) had relatively negative attitudes, controlling for other factors. Previous experiences with more ePRO types were associated with more positive attitudes (β = 0.08, P = .02). Similar correlates were found with PU but not with PEU. CONCLUSION This study revealed that CRPs had various experiences with ePRO systems and attitudes toward technology. Age, working years, and previous experiences with ePROs were correlates of overall attitude toward technology and PU. These findings suggest necessary targeted training to facilitate ePRO use in oncology clinical trials by improving CRPs' awareness and attitude toward technology.
The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories
Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Compton, Kelly, Xu, Rixing, Mishra, Rashmi , Drangsholt, Mark, Antunes, José Leopoldo Ferreira , Acheson, Alistair, Lu, Dan , Wallace, Lindsey E., Kocarnik, Jonathan , Fu, Weijia , Dean, Frances , Pennini, Alyssa, Henrikson, Hannah , Alam, Shazia , Ababneh, Emad , Abdoun, Meriem , Abidi, Hassan , Ali, Hiwa Abubaker, Adane, Tigist Demssew , Ahmad, Aqeel , Rashid, Tarik A. , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Aravkin, Aleksandr Y. , Aruleba, Raphael Taiwo , Azadnajafabad, Sina , Azangou‐Khyavy, Mohammadreza , Badar, Muhammad , Barqawi, Hiba Jawdat , Bashir, Nasir Zeeshan , Bashiri, Azadeh, Benzian, Habib , Bhagat, Devidas S. , Bhojaraja, Vijayalakshmi S, Bouaoud, Souad, Braithwaite, Dejana , Брико, Н. И. , Chakraborty, Promit Ananyo , Chattu, Vijay Kumar , Chaurasia, Akhilanand , Chen, Mengxuan , Cho, William C. , Chu, Dinh‐Toi , Chukwu, Isaac Sunday , Chung, Eunice, Martins, Natália , Dadras, Omid , Dandona, Lalit , Dandona, Rakhi , Daneshpajouhnejad, Parnaz , Molla, Meseret Derbew , Dessalegn, Fikadu Nugusu, Digesa, Lankamo Ena , Dixit, Shilpi Gupta , Dixit, Abhinav , Djalalinia, Shirin , Tantawi, Maha El , Enyew, Daniel Berhanie, Erku, Daniel , Ezzeddini, Rana, Fagbamigbe, Adeniyi Francis , Falzone, Luca , Fetensa, Getahun, Fukumoto, Takeshi , Gebrehiwot, Mesfin , Ghashghaee, Ahmad , Golechha, Mahaveer , Goleij, Pouya , Gorini, Giuseppe , Guimarães, André Luiz Sena , Gupta, Sapna , Halboub, Esam , Hanif, Asif , Harorani, Mehdi , Hasani, Hamidreza, Hassan, Abbas M. , Hassen, Mohammed Bheser, Hay, Simon I , Herrera-Serna, Brenda Yuliana , Hosseinzadeh, Mehdi , Ilić, Irena , Isola, Gaetano , Jaiswal, Abhishek , Jani, Chinmay , Javaheri, Tahereh , Jayaram, Shubha, Joseph, Nitin , Kadashetti, Vidya, Karanth, Shama D. , Kaur, Harkiran , Keykhaei, Mohammad , Khader, Yousef , Khajuria, Himanshu , Khanali, Javad , Khatib, Mahalaqua Nazli , Kashani, Hamid Reza Khayat , Kim, Min Seo , Kompani, Farzad , Kurmi, Om , Lal, Dharmesh Kumar, Lee, Yo Han , Lim, Stephen S , Listl, Stefan , Lopukhov, Platon D , Mafi, Ahmad R , Malik, Ahmad Azam , Maulud, Sazan Qadir , Nasab, Entezar Mehrabi, Mirfakhraie, Reza , Misganaw, Awoke, Misra, Sanjeev , Mithra, Prasanna , Mohammad, Yousef , Moni, Mohammad Ali , Moraga, Paula , Mubarik, Sumaira , Murray, Christopher J L , Swamy, Sreenivas Narasimha, Narayana, Aparna Ichalangod, Nassereldine, Hasan , Natto, Zuhair S. , Nayak, Biswa Prakash , Negru, Șerban , Nggada, Haruna Asura , Núñez-Samudio, Virginia , Oancea, Bogdan , Padrón‐Monedero, Alicia , Pandey, Anamika , Patel, Jay , Pezzani, Raffaele , Piracha, Zahra Zahid , Rabiee, Navid , Radhakrishnan, Venkatraman , Rahmani, Amir M. , Rao, Sowmya J, Rath, Goura Kishor, Rawaf, David Laith , Rawassizadeh, Reza , Rezaei, Nazila, Rezapour, Aziz , Riad, Abanoub , Romero‐Rodríguez, Esperanza , Manjula, S, Chandan, S N , Saddik, Basema , Saeed, Umar , Safaei, Mohsen , Sahebazzamani, Maryam , Samy, Abdallah M , Santric-Milicevic, Milena M , Sathian, Brijesh , Satpathy, Maheswar , Šekerija, Mario , Senthilkumaran, Subramanian , Seylani, Allen, Shafaat, Omid , Sharew, Mequannent Melaku Sharew, Sharifi‐Rad, Javad , Shorofi, Seyed Afshin, Shrestha, Sunil , Malleshappa, Sudeep K Siddappa , Singh, Paramdeep , Sinha, Dhirendra Narain , Solomon, Yonatan , Suleman, Muhammad , Abdulkader, Rizwan Suliankatchi , Abkenar, Yasaman Taheri, Tan, Ker‐Kan , Tbakhi, Abdelghani, Thiyagarajan, Arulmani , Tovani‐Palone, Marcos Roberto , Volovăț, Simona Ruxandra , Westerman, Ronny, Wickramasinghe, Nuwan Darshana , Xiao, Hong , Zadnik, Vesna, Zare, Iman, Zhang, Zhi-Jiang , Force, Lisa M , Hugo, Fernando Neves , Hoogar, Praveen , Rezaei, Nazila , Rezaei, Nazila , Shivakumar, KM , Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Cunha, Amanda Ramos da , Kerr, Alexander Ross , Wallace, Lindsey E., Abd‐Elsalam, Sherief , Abu‐Gharbieh, Eman , Addo, Isaac Yeboah , Ahmad, Sajjad , Akonde, Maxwell , Al‐Maweri, Sadeq Ali , Alsharif, Ubai , Ansari‐Moghaddam, Alireza , Anwar, Sumadi Lukman, Arabloo, Jalal , Asaad, Malke, Ashraf, Tahira , Athari, Seyyed Shamsadin , Attia, Sameh , Baghcheghi, Nayereh , Banach, Maciej , Bardhan, Mainak , Bernabé, Eduardo , Bjørge, Tone , Călina, Daniela Cornelia , Carreras, Giulia , Dai, Xiaochen , Soltani, Reza Darvishi Cheshmeh , Darwesh, Aso Mohammad , Debela, Sisay Abebe , Dianatinasab, Mostafa , Sayed, Iman El , Gaewkhiew, Piyada , Gallus, Silvano , Gill, Paramjit Singh , Gomez, Ricardo Santiago , Gupta, Bhawna , Gupta, Veer Bala , Gupta, Vivek , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hariyani, Ninuk , Hassanipour, Soheil , Hayat, Khezar , Holla, Ramesh , Horita, Nobuyuki , Hussain, Salman , Ilesanmi, Olayinka Stephen , Ilić, Milena , Jayarajah, Umesh , Kandaswamy, Eswar , Karaye, Ibraheem M. , Kauppila, Joonas H. , Tabari, Mohammad Amin Khazeei , Koohestani, Hamid Reza , Kumar, G Anil , Vecchia, Carlo La , Lal, Dharmesh Kumar, Landires, Iván , Lasrado, Savita , Ledda, Caterina , Libra, Massimo , Mahumud, Rashidul Alam , Mathur, Manu Raj , Meena, Jitendra Kumar , Meštrović, Tomislav , Mohammadi, Mokhtar, Mohammadi, Esmaeil , Mokdad, Ali H. , Morrison, Shane D. , Mozaffari, Hamid Reza , Nair, Tapas Sadasivan , Nouraei, Hasti , Olagunju, Andrew T , Bali, Ahmed Omar , Padubidri, Jagadish Rao , Pardhan, Shahina , Radhakrishnan, Raghu , Rahmani, Amir Masoud, Rahmanian, Vahid , Rao, Chythra R , Rawaf, Salman , Razeghinia, Mohammad Sadegh , Rezaei, Negar , Rezaei, Nima , Rezapour, Aziz , Roberts, Thomas J. , Roshandel, Gholamreza , Saeb, Mohammad Reza , Sahebkar, Amirhossein , Farrokhi, Amir Salek , Shahsavari, Hamid R. , Shamsoddin, Erfan , Shetty, Jeevan K. , Shivakumar, K. M. , Shobeiri, Parnian , Singh, Jasvinder A. , Singh, Garima Prateek , Talaat, Iman Mamdouh , Tiyuri, Amir , Unnikrishnan, Bhaskaran , Vo, Bay, Wang, Cong , Yu, Chuanhua , Yüce, Deniz , Yunusa, Ismaeel , Zoladl, Mohammad , Alahdab, Fares

Mayo Clinic

JAMA Oncology | September 7, 2023 | Volume: 9 | Issue: 10 | Pages: 1401

10.1001/jamaoncol.2023.2960 | PMID 37676656 Get It

ImportanceLip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning.ObjectiveTo analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates.Evidence ReviewThe incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019.FindingsIn 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia.Conclusions and RelevanceIn this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.